Lund, Sweden — 30 December 2019 — As previously announced, Camurus has carried out a directed share issue. The directed share issue has resulted in changes in the number of shares and votes in Camurus as follows:
Prior to the directed share issue, the total number of shares in Camurus amounted to 47,976,858, corresponding to 47,976,858 votes. The number of shares and votes has as a result of the directed share issue increased by 3,660,000 shares and votes. As of 30 December 2019, the total number of shares in Camurus amounts to 51,636,858, corresponding to 51,636,858 votes.
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
The information is such that Camurus AB is obliged to make public pursuant to Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act. The information was submitted for publication on 30 December 2019 at 08:00 CET.